- Home
- AVIR vs DMRC Comparison
AVIR vs DMRC Comparison
Compare AVIR & DMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- DMRC
- Stock Information
- Founded
- AVIR 2012
- DMRC 2008
- Country
- AVIR United States
- DMRC United States
- Employees
- AVIR N/A
- DMRC N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- DMRC EDP Services
- Sector
- AVIR Health Care
- DMRC Technology
- Exchange
- AVIR Nasdaq
- DMRC Nasdaq
- Market Cap
- AVIR 273.0M
- DMRC 275.4M
- IPO Year
- AVIR 2020
- DMRC N/A
- Fundamental
- Price
- AVIR $3.90
- DMRC $12.17
- Analyst Decision
- AVIR Hold
- DMRC Strong Buy
- Analyst Count
- AVIR 1
- DMRC 1
- Target Price
- AVIR $6.00
- DMRC $30.00
- AVG Volume (30 Days)
- AVIR 426.9K
- DMRC 137.0K
- Earning Date
- AVIR 08-06-2025
- DMRC 08-14-2025
- Dividend Yield
- AVIR N/A
- DMRC N/A
- EPS Growth
- AVIR N/A
- DMRC N/A
- EPS
- AVIR N/A
- DMRC N/A
- Revenue
- AVIR N/A
- DMRC $37,848,000.00
- Revenue This Year
- AVIR N/A
- DMRC N/A
- Revenue Next Year
- AVIR N/A
- DMRC $4.21
- P/E Ratio
- AVIR N/A
- DMRC N/A
- Revenue Growth
- AVIR N/A
- DMRC 2.44
- 52 Week Low
- AVIR $2.46
- DMRC $10.44
- 52 Week High
- AVIR $4.15
- DMRC $48.32
- Technical
- Relative Strength Index (RSI)
- AVIR 67.66
- DMRC 38.24
- Support Level
- AVIR $3.36
- DMRC $12.21
- Resistance Level
- AVIR $3.53
- DMRC $12.88
- Average True Range (ATR)
- AVIR 0.15
- DMRC 0.46
- MACD
- AVIR -0.00
- DMRC -0.08
- Stochastic Oscillator
- AVIR 97.24
- DMRC 3.64
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.